MSLN targeting DNA vaccine for cancer immunotherapy
AssigneeVaximm AG
InventorsMarco Springer, Heinz Lubenau
Life of this patent
Estimating the term…
Abstract
The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
Claims12
A method for treating or vaccinating a patient against a cancer comprising administering to the patient an attenuated mutant strain of Salmonella comprising at least one copy of a recombinant DNA molecule comprising an expression cassette encoding Mesothelin (MSLN), wherein the MSLN is human MSLN, the attenuated mutant strain of Salmonella is Salmonella typhi Ty21a, and wherein the expression cassette is a eukaryotic expression cassette.
Dependencies are inferred from the claim text.